NAUT

Company Overview — What Does Nautilus Biotechnology, Inc. Do?

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology, Inc. (NAUT) is classified as a small-cap stock in the Technology sector, specifically within the Measuring And Control Equipment industry. The company is led by CEO Sujal M. Patel and employs approximately 130 people. With a market capitalization of $425M, NAUT is one of the notable companies in the Technology sector.

Nautilus Biotechnology, Inc. (NAUT) Stock Rating — Hold (April 2026)

As of April 2026, Nautilus Biotechnology, Inc. receives a Hold rating with a composite score of 36.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.NAUT ranks #1,963 out of 4,446 stocks in our coverage universe. Within the Technology sector, Nautilus Biotechnology, Inc. ranks #218 of 584 stocks, placing it in the upper half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NAUT Stock Price and 52-Week Range

Nautilus Biotechnology, Inc. (NAUT) currently trades at $3.01. The stock lost $0.03 (1.0%) in the most recent trading session. The 52-week high for NAUT is $3.08, which means the stock is currently trading -2.3% from its annual peak. The 52-week low is $0.62, putting the stock 385.5% above its annual trough. Recent trading volume was 393K shares, suggesting relatively thin trading activity.

Is NAUT Overvalued or Undervalued? — Valuation Analysis

Nautilus Biotechnology, Inc. (NAUT) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.52x, versus the sector average of 3.16x.

At current multiples, Nautilus Biotechnology, Inc. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nautilus Biotechnology, Inc. Profitability — ROE, Margins, and Quality Score

Nautilus Biotechnology, Inc. (NAUT) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -39.3%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.3% versus the sector average of -1.0%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NAUT Debt, Balance Sheet, and Financial Health

Nautilus Biotechnology, Inc. has a debt-to-equity ratio of 22.0%, compared to the Technology sector average of 43.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 13.33x, indicating strong short-term liquidity.

NAUT has a beta of 1.66, meaning it is more volatile than the broader market — a $10,000 investment in NAUT would be expected to move 66.0% more than the S&P 500 on any given day. The stability factor score for Nautilus Biotechnology, Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Nautilus Biotechnology, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nautilus Biotechnology, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.47. Net income for the quarter was $-62M.

In FY 2025, Nautilus Biotechnology, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.47. Net income for the quarter was $-59M.

In Q3 2025, Nautilus Biotechnology, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.11. Net income for the quarter was $-14M.

In Q2 2025, Nautilus Biotechnology, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.12. Net income for the quarter was $-15M.

Over the past 8 quarters, Nautilus Biotechnology, Inc. has reported varying levels of revenue. Investors analyzing NAUT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NAUT Dividend Yield and Income Analysis

Nautilus Biotechnology, Inc. (NAUT) does not currently pay a dividend. This is common among smaller companies in the Measuring And Control Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

NAUT Momentum and Technical Analysis Profile

Nautilus Biotechnology, Inc. (NAUT) has a momentum factor score of 77/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 27/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

NAUT vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, Nautilus Biotechnology, Inc. (NAUT) ranks #218 out of 584 stocks based on the Blank Capital composite score. This places NAUT in the upper half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing NAUT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NAUT vs S&P 500 (SPY) comparison to assess how Nautilus Biotechnology, Inc. stacks up against the broader market across all factor dimensions.

NAUT Next Earnings Date

No upcoming earnings date has been announced for Nautilus Biotechnology, Inc. (NAUT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NAUT? — Investment Thesis Summary

Nautilus Biotechnology, Inc. presents a balanced picture with arguments on both sides. The quality score of 20/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. Price momentum is positive at 77/100, suggesting the trend favors buyers. High volatility (stability score 21/100) increases portfolio risk.

In summary, Nautilus Biotechnology, Inc. (NAUT) earns a Hold rating with a composite score of 36.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NAUT stock.

Related Resources for NAUT Investors

Explore more research and tools: NAUT vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NAUT head-to-head with peers: NAUT vs IHS, NAUT vs VRSN, NAUT vs ESE.